/
ALEC
$2.01-$0.11 (-5.12%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$240.1M
112M shares
52-week range
$1.09 – $3.40
40% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-25.44
Alector, Inc. Common Stock
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
www.alector.com- Employees
- 103
- IPO / List date
- Feb 7, 2019
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ALEC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,287,691 | $2.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALEC yet.
